Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PDE9A | O76083 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 15/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 15/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 15/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 13/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 0.41 |
| ▸ | TSHR | P16473 | 12/20 | 0.41 |
| ▸ | USP2 | O75604 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23217009 | 0.90 | ALDH1A1 (0.42) | NPC1PKMRAB9APDE9ACYP1A2 | |
| SCHEMBL29844240 | 0.90 | ALDH1A1 (0.42) | NPC1PKMRAB9APDE9ACYP1A2 | |
| SCHEMBL24651143 | 0.89 | CYP1A2 (0.46) | NPC1PKMRAB9APDE9ACYP1A2 | |
| SCHEMBL27217791 | 0.87 | NPC1 (0.42) | NPC1PKMRAB9APDE9ACYP1A2 | |
| SCHEMBL25230106 | 0.85 | KMT2A (0.42) | PDE9ATSHRALDH1A1MAPK1MEN1 | |
| SCHEMBL30497632 | 0.85 | KMT2A (0.42) | PDE9ATSHRALDH1A1MAPK1MEN1 | |
| SCHEMBL27217855 | 0.85 | CYP1A2 (0.46) | PDE9ACYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL21903703 | 0.84 | CYP1A2 (0.38) | NPC1PKMRAB9APDE9ACYP1A2 | |
| SCHEMBL20645215 | 0.84 | PDE9A (0.48) | NPC1PKMRAB9APDE9ACYP1A2 | |
| SCHEMBL22902838 | 0.84 | CYP1A2 (0.38) | NPC1PKMRAB9ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158394-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-05-16 | — | — | US | disclosed |
| WO-2024059200-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-03-21 | — | — | WO | disclosed |
| CN-117597346-A | NEK7 inhibitors | 哈利亚治疗公司 | 2024-02-23 | — | — | CN | disclosed |
| EP-4320127-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| CN-116075513-A | Inhibitors of NEK7 kinase | 哈利亚治疗公司 | 2023-05-05 | — | — | CN | disclosed |
| EP-4161933-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| WO-2022216680-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022212326-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022212326-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2022-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158394-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | NPC1 241/4885PKM 1518/4885RAB9A 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.